RCUS - CIK 0001724521
Arcus Biosciences, Inc. (RCUS) reported revenue of $33.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $33.00M | -35.3% |
| FY 2024 | $51.00M | -56.4% |
| FY 2023 | $117.00M | +207.9% |
| FY 2022 | $38.00M | -90.1% |
| FY 2021 | $383.00M | +391.0% |
| FY 2020 | $78.00M | +420.0% |
| FY 2019 | $15.00M | +79.6% |
| FY 2018 | $8.35M | +491.2% |
| FY 2017 |
Arcus Biosciences, Inc. (RCUS) reported revenue of $33.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Arcus Biosciences, Inc.'s revenue grew from $1.41M to $33.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.41M |
| - |